Over 65 million people suffer from recurrent, unprovoked seizures. The lack of validated
biomarkers specific for myriad forms of epilepsy makes diagnosis challenging. Diagnosis …

Epilepsy is a neurological disease characterized by excessive and abnormal hyper-
synchrony of electrical discharges of the brain and a predisposition to generate epileptic …

Abstract Aims The prognosis of Infantile epileptic spasm syndrome (IESS), relates to the
underlying etiology and delay in controlling epileptic spasms. Based on the spasm-free rate …

Objective Seizures are common in critically ill children and neonates, and these patients
would benefit from intravenous (IV) antiseizure medications with few adverse effects. We …

Background: Oxcarbazepine is thought to be better-tolerated and less susceptible to drug–
drug interactions than its predecessor, carbamazepine. Genetic testing for HLA-B* 15: 02 is …

Introduction There is a very wide spectrum of epilepsies and developmental and epileptic
encephalopathies that affect children, from self-limited forms, not necessarily requiring …

Objective The management of antiseizure treatment in patients with epilepsy relies on the
benefit–risk ratio. Data on antiseizure medication (ASM) use in children are limited. We …

The pharmacological activity of oxcarbazepine (OXC) is primarily exerted through its active
10‐monohydroxy metabolite (MHD). Nonetheless, there is limited pharmacokinetic …

Objective Here we present a multicenter series of patients with developmental epileptic
encephalopathies (DEE) who were treated with brivaracetam (BRV) as add-on therapy …

We read with great interest the report by Sourbron et al. 1 entitled “Medical Treatment in
Infants and Young Children with Epilepsy: Off‐label Use of Antiseizure Medications. Survey …